Advocacy intelligence hub — real-time data for patient organizations
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — EARLY_PHASE1
Stanford University — PHASE1, PHASE2
Tr1X, Inc. — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
VIGABATRIN
(VIGABATRIN)standardHikma Pharmaceuticals USA Inc
Anti-epileptic Agent [EPC]
12.1 Mechanism of Action The precise mechanism of vigabatrin’s anti-seizure effect is unknown, but it is believed to be the result of its action as an...
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
Jessie Alexander, MD
Stanford University
Veronika Bachanova, MD, PhD, MD
University of Minnesota
📍 MINNEAPOLIS, MN
Thomas A Waldmann, M.D.
National Cancer Institute (NCI)
Luca Elli
Fondazione IRCCS Cà Granda
Daniel A Leffler
Beth Israel Deaconess Medical Center
📍 BOSTON, MA